AbCellera Biologics Inc. reported a significant decline in financial performance for the second quarter of 2026, with total revenue dropping to $4.05 million, a 76% decrease from $17.08 million in the same period of 2025. For the first half of 2026, revenue also fell by 42% to $12.36 million compared to $21.32 million in the prior year. The decline was primarily attributed to a substantial reduction in licensing and royalty revenue, which plummeted by 99% to $149,000 in Q2 2026, and a 41% decrease in research fees. The company noted that the timing and progress of its research and development efforts contributed to this downturn.
Operating expenses remained relatively stable, totaling $66.83 million for the second quarter of 2026, compared to $66.67 million in the same quarter of 2025. Research and development expenses increased by 17% to $45.99 million, reflecting ongoing investments in clinical trials and internal programs. Conversely, sales, general, and administrative expenses decreased by 37% to $13.85 million, attributed to a reduction in legal fees following a settlement in December 2025 and optimization of headcount. The net loss for the quarter widened to $55.43 million, compared to a loss of $34.73 million in Q2 2025.
In terms of strategic developments, AbCellera entered into a collaboration agreement with Jazz Pharmaceuticals in June 2026, receiving a $56 million upfront payment for research and development of next-generation T-cell engaging antibodies. Additionally, in July 2026, the company announced a collaboration with Vertex Pharmaceuticals, which included another $28 million upfront payment. These agreements are expected to enhance future revenue streams as they progress through clinical development.
Operationally, AbCellera reported a decrease in the number of partner-led programs with downstream potential, from 44 at the end of 2025 to 35 by June 2026. The company currently has three molecules in clinical trials, down from five, indicating a strategic focus on fewer, more promising candidates. The total cash, cash equivalents, and marketable securities as of June 30, 2026, stood at $540.1 million, reflecting a slight increase from $533.8 million at the end of 2025, bolstered by the recent upfront payments and the full receipt of a $36 million litigation settlement.
Looking ahead, AbCellera remains focused on advancing its internal pipeline and enhancing its antibody discovery capabilities. The company anticipates that future revenue will be positively impacted by the recognition of revenue from recent collaborations and ongoing research obligations. However, the uncertainty surrounding the development and commercialization of its drug candidates continues to pose risks to its financial outlook. The company plans to maintain its investment in research and development while optimizing its operational efficiencies to navigate the challenges ahead.
About AbCellera Biologics Inc.
AbCellera Biologics Inc. specializes in discovering and developing antibody-based medicines for diseases with high unmet needs. The company integrates advanced technology, data science, and automation to accelerate antibody drug discovery from target identification to clinical candidate delivery. Serving biotechnology and pharmaceutical partners primarily in the U.S. and Europe, AbCellera’s business model combines proprietary internal programs with strategic collaborations, generating value through milestone payments, royalties, and equity stakes.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov